JP2021528973A5 - - Google Patents

Info

Publication number
JP2021528973A5
JP2021528973A5 JP2020572396A JP2020572396A JP2021528973A5 JP 2021528973 A5 JP2021528973 A5 JP 2021528973A5 JP 2020572396 A JP2020572396 A JP 2020572396A JP 2020572396 A JP2020572396 A JP 2020572396A JP 2021528973 A5 JP2021528973 A5 JP 2021528973A5
Authority
JP
Japan
Prior art keywords
seq
antigen
binding protein
amino acid
domain
Prior art date
Application number
JP2020572396A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020010079A5 (https=
JP2021528973A (ja
JP7633810B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/040296 external-priority patent/WO2020010079A2/en
Publication of JP2021528973A publication Critical patent/JP2021528973A/ja
Publication of JPWO2020010079A5 publication Critical patent/JPWO2020010079A5/ja
Publication of JP2021528973A5 publication Critical patent/JP2021528973A5/ja
Priority to JP2025018997A priority Critical patent/JP2025076471A/ja
Application granted granted Critical
Publication of JP7633810B2 publication Critical patent/JP7633810B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020572396A 2018-07-02 2019-07-02 抗steap1抗原結合タンパク質 Active JP7633810B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025018997A JP2025076471A (ja) 2018-07-02 2025-02-07 抗steap1抗原結合タンパク質

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862693216P 2018-07-02 2018-07-02
US62/693,216 2018-07-02
US201962800259P 2019-02-01 2019-02-01
US62/800,259 2019-02-01
PCT/US2019/040296 WO2020010079A2 (en) 2018-07-02 2019-07-02 Anti-steap1 antigen-binding protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025018997A Division JP2025076471A (ja) 2018-07-02 2025-02-07 抗steap1抗原結合タンパク質

Publications (4)

Publication Number Publication Date
JP2021528973A JP2021528973A (ja) 2021-10-28
JPWO2020010079A5 JPWO2020010079A5 (https=) 2022-07-12
JP2021528973A5 true JP2021528973A5 (https=) 2022-07-12
JP7633810B2 JP7633810B2 (ja) 2025-02-20

Family

ID=67441644

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020572396A Active JP7633810B2 (ja) 2018-07-02 2019-07-02 抗steap1抗原結合タンパク質
JP2025018997A Pending JP2025076471A (ja) 2018-07-02 2025-02-07 抗steap1抗原結合タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025018997A Pending JP2025076471A (ja) 2018-07-02 2025-02-07 抗steap1抗原結合タンパク質

Country Status (23)

Country Link
US (4) US11530274B2 (https=)
EP (1) EP3817770A2 (https=)
JP (2) JP7633810B2 (https=)
KR (1) KR20210028204A (https=)
CN (1) CN112584859A (https=)
AU (1) AU2019299357A1 (https=)
BR (1) BR112020026724A2 (https=)
CA (1) CA3104386A1 (https=)
CL (2) CL2020003391A1 (https=)
CO (1) CO2021000497A2 (https=)
CR (1) CR20210047A (https=)
IL (1) IL279355A (https=)
JO (1) JOP20200343A1 (https=)
MA (1) MA53094A (https=)
MX (2) MX2021000163A (https=)
MY (1) MY208638A (https=)
PE (1) PE20211091A1 (https=)
PH (1) PH12020552270A1 (https=)
SA (1) SA521420953B1 (https=)
SG (1) SG11202013138RA (https=)
TW (2) TW202519260A (https=)
UY (1) UY38289A (https=)
WO (1) WO2020010079A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US11053316B2 (en) * 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
CN110894240B (zh) 2014-11-26 2022-04-15 森科股份有限公司 结合cd3和肿瘤抗原的异二聚体抗体
EA202190304A1 (ru) * 2018-07-18 2022-01-21 Эмджен Инк. Химерные рецепторы к steap1 и способы их применения
US20210301020A1 (en) * 2018-07-24 2021-09-30 Amgen Inc. Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
JP2024511319A (ja) 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Cd3及びcldn6に結合するヘテロ二量体抗体
WO2023212559A1 (en) 2022-04-26 2023-11-02 Amgen Inc. Lyophilization method
CA3261989A1 (en) * 2022-07-22 2024-01-25 Genentech, Inc. ANTI-STEAP1 ANTIGEN-BINDING MOLECULES AND THEIR USES
WO2025042872A1 (en) 2023-08-21 2025-02-27 Amgen Research (Munich) Gmbh Combination therapy for treating prostate cancer
WO2025042865A1 (en) 2023-08-21 2025-02-27 Amgen Research (Munich) Gmbh Methods for treating prostate cancer with bispecific antibodies binding steap1xcd3
WO2025122824A1 (en) * 2023-12-08 2025-06-12 Nutcracker Therapeutics, Inc. Multivalent antibody constructs for targeting prostate cancer cells
WO2025128807A1 (en) 2023-12-13 2025-06-19 Amgen Inc. Radiolabeled compounds for the detection of steap1
WO2025240781A2 (en) * 2024-05-15 2025-11-20 Werewolf Therapeutics, Inc. Modified antibodies and immunoglobulin formats
WO2026039321A1 (en) 2024-08-12 2026-02-19 Amgen, Inc. Methods for treating prostate cancer

Family Cites Families (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4169888A (en) 1977-10-17 1979-10-02 The Upjohn Company Composition of matter and process
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1987006265A1 (fr) 1986-04-17 1987-10-22 Kyowa Hakko Kogyo Co., Ltd. Nouveaux composes dc-88a et dc-89a1, et procede pour leur preparation
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
US5084468A (en) 1988-08-11 1992-01-28 Kyowa Hakko Kogyo Co., Ltd. Dc-88a derivatives
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2598116B2 (ja) 1988-12-28 1997-04-09 協和醗酵工業株式会社 新規物質dc113
JP2510335B2 (ja) 1989-07-03 1996-06-26 協和醗酵工業株式会社 Dc―88a誘導体
US5187186A (en) 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0530225A4 (en) 1990-05-07 1993-09-22 Scripps Clinic And Research Foundation Intermediates in the formation of the calicheamicin and esperamicin oligosaccharides
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
KR100332254B1 (ko) 1993-10-01 2002-09-27 데이꼬꾸 조끼 세이야꾸 가부시키가이샤 신규인펩티드유도체
CA2165819C (en) 1994-04-22 2005-12-27 Nobuyoshi Amishiro Dc-89 derivatives
JPH07309761A (ja) 1994-05-20 1995-11-28 Kyowa Hakko Kogyo Co Ltd デュオカルマイシン誘導体の安定化法
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5550246A (en) 1994-09-07 1996-08-27 The Scripps Research Institute Calicheamicin mimics
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
ATE234635T1 (de) 1995-12-22 2003-04-15 Bristol Myers Squibb Co Verzweigte hydrazongruppen enthaltende kuppler
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
EP0915987A2 (en) 1997-04-21 1999-05-19 Donlar Corporation POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
CZ302070B6 (cs) 1998-04-21 2010-09-29 Micromet Ag Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
AU757698C (en) 1998-06-01 2004-04-08 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
US7449443B2 (en) 2000-03-23 2008-11-11 California Institute Of Technology Method for stabilization of proteins using non-natural amino acids
EP1299419A2 (en) 2000-05-24 2003-04-09 Imclone Systems, Inc. Bispecific immunoglobulin-like antigen binding proteins and method of production
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
CA2424977C (en) 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
ES2639222T5 (es) 2000-10-06 2023-11-24 Kyowa Kirin Co Ltd Células que producen unas composiciones de anticuerpo
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US20030003097A1 (en) 2001-04-02 2003-01-02 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with GnTIII
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7129261B2 (en) 2001-05-31 2006-10-31 Medarex, Inc. Cytotoxic agents
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
ES2537074T3 (es) * 2001-09-06 2015-06-02 Agensys, Inc. Ácido nucleico y proteína correspondiente denominados STEAP-1 útiles en el tratamiento y la detección de cáncer
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
US7139665B2 (en) 2002-02-27 2006-11-21 California Institute Of Technology Computational method for designing enzymes for incorporation of non natural amino acids into proteins
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
JP2006507322A (ja) 2002-11-14 2006-03-02 シンタルガ・ビーブイ 多重自己脱離放出スペーサーとして構築されたプロドラッグ
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
PL3524611T3 (pl) 2003-05-20 2021-06-14 Immunogen, Inc. Udoskonalone czynniki cytotoksyczne zawierające nowe maitansynoidy
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
SI1629011T1 (sl) 2003-05-31 2010-05-31 Micromet Ag Humane molekule za vezavo anti hu cd
CA2522586C (en) 2003-05-31 2017-02-21 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
EP1675620B1 (en) 2003-10-09 2019-05-08 Ambrx, Inc. Polymer derivatives
DE602004030811D1 (de) 2003-10-16 2011-02-10 Micromet Ag Multispezifische deimmunisierte cd3-bindende moleküle
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
CA2548817A1 (en) 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
EP2327724A3 (en) 2004-02-02 2011-07-27 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
ES2443996T3 (es) 2004-04-22 2014-02-21 Agensys, Inc. Anticuerpos y moléculas derivadas de los mismos que se unen a proteínas STEAP-1
JP4806680B2 (ja) 2004-05-19 2011-11-02 メダレックス インコーポレイテッド 自己犠牲リンカー及び薬剤複合体
RU2402548C2 (ru) 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
JP2008512352A (ja) 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド 新規な四価の二重特異性抗体
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
CA2617907A1 (en) 2005-08-05 2007-02-15 Syntarga B.V. Triazole-containing releasable linkers and conjugates comprising the same
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
EP1994000B1 (en) 2006-02-02 2017-08-23 Syntarga B.V. Water-soluble cc-1065 analogs and their conjugates
KR20140116546A (ko) 2006-10-27 2014-10-02 제넨테크, 인크. 항체 및 면역접합체 및 이들의 용도
JP5394246B2 (ja) 2007-03-30 2014-01-22 ジェネンテック, インコーポレイテッド 抗体及びイムノコンジュゲートとこれらの使用方法
CA2695297C (en) 2007-08-01 2017-03-21 Syntarga B.V. Substituted cc-1065 analogs and their conjugates
CA2697922A1 (en) 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Compositions that bind multiple epitopes of igf-1r
US8163551B2 (en) 2008-05-02 2012-04-24 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US8715964B2 (en) 2008-05-11 2014-05-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Expression of IL-12 family heterodimers
AU2009320481C1 (en) 2008-11-03 2016-12-08 Syntarga B.V. Novel CC-1065 analogs and their conjugates
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
RU2613886C2 (ru) 2010-06-03 2017-03-21 Дженентек, Инк. Антитела и иммуноконъюгаты, визуализируемые при помощи иммуно-позитрон-эмиссионной томографии, и способы их применения
BR112012030311A2 (pt) 2010-06-08 2017-01-24 Genentech Inc anticorpo
EP3029066B1 (en) 2010-07-29 2019-02-20 Xencor, Inc. Antibodies with modified isoelectric points
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
US9683052B2 (en) 2011-03-25 2017-06-20 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
BR112014012882A2 (pt) 2011-11-29 2017-06-13 Genentech Inc método, anticorpo, polinucleotídeo, célula hospedeira, linhagem celular de hibridoma, uso do anticorpo e kit
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
US8820052B2 (en) 2012-02-09 2014-09-02 Ford Global Technologies, Llc Liquid reductant system and method for operation of the liquid reductant system
SG10201608307WA (en) 2012-04-20 2016-11-29 Emergent Product Dev Seattle Cd3 binding polypeptides
CN104271602B (zh) 2012-11-21 2020-08-21 武汉友芝友生物制药有限公司 双特异性抗体
CA2898100C (en) 2013-01-14 2023-10-10 Xencor, Inc. Novel heterodimeric proteins
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
EP2970483A2 (en) 2013-03-15 2016-01-20 Amgen Inc. Methods and compositions relating to anti-ccr7 antigen binding proteins
WO2014165818A2 (en) 2013-04-05 2014-10-09 T Cell Therapeutics, Inc. Compositions and methods for preventing and treating prostate cancer
US20170043034A1 (en) 2014-01-24 2017-02-16 Genentech, Inc. Methods of using anti-steap1 antibodies and immunoconjugates
JP6775422B2 (ja) 2014-03-28 2020-10-28 ゼンコー・インコーポレイテッドXencor、 Inc. Cd38及びcd3に結合する二重特異性抗体
US9777073B2 (en) 2014-07-21 2017-10-03 Wuhan Yzy Biopharma Co., Ltd. Construction and application of bispecific antibody EpCAM×CD3
US9611325B2 (en) 2014-07-21 2017-04-04 Wuhan Yzy Biopharma Co., Ltd. Construction and application of bispecific antibody HER2xCD3
MX2017003123A (es) 2014-09-12 2017-05-12 Genentech Inc Anticuerpos y conjugados modificados geneticamente con cisteina.
BR112017011166A2 (pt) 2014-11-26 2018-02-27 Xencor, Inc. anticorpos heterodiméricos que se ligam a cd3 e cd38
CN113552350B (zh) 2015-04-21 2024-10-11 基因泰克公司 用于前列腺癌分析的组合物和方法
EP3778640A1 (en) 2015-05-01 2021-02-17 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
LT3353212T (lt) 2015-09-23 2021-12-27 Regeneron Pharmaceuticals, Inc. Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas
WO2017055388A2 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
US20190048094A1 (en) 2016-02-24 2019-02-14 Oncomed Pharmaceuticals, Inc. Redirecting immune responses
SI3468586T1 (sl) 2016-06-14 2025-01-31 Xencor, Inc. Bispecifična protitelesa za zaviralce kontrolnih točk
SG11201909218RA (en) 2017-04-03 2019-11-28 Hoffmann La Roche Antibodies binding to steap-1
UY38080A (es) 2018-02-08 2019-08-30 Amgen Inc FORMULACIÓN FARMACÉUTICA DE pH BAJO
EA202190304A1 (ru) * 2018-07-18 2022-01-21 Эмджен Инк. Химерные рецепторы к steap1 и способы их применения
EP4375015A1 (en) * 2022-11-24 2024-05-29 Manuel Dimas Vargas Munoz Device for supporting bits for a tool

Similar Documents

Publication Publication Date Title
JP2021528973A5 (https=)
JP7551693B2 (ja) NKp46結合タンパク質の可変領域
AU2020359928B2 (en) CD3-targeting antibody, bispecific antibody and use thereof
US10781256B2 (en) Anti SIRP-α antibodies and bi-specific macrophage enhancing antibodies
US20260062493A1 (en) Antibody Targeting BCMA, Bispecific Antibody, And Use Thereof
JP7489468B2 (ja) 二重特異性融合タンパク質及びその応用
JP2019216719A (ja) Cd47に対するヒト化及びキメラモノクローナル抗体
JP2019533719A5 (https=)
JPWO2019129221A5 (https=)
JPWO2020010079A5 (https=)
CA3228641A1 (en) Fap/cd40 binding molecule and medicinal use thereof
JP2024001073A5 (https=)
JP2025503513A (ja) Cd3を標的にする抗体、多特異性抗体、およびその使用
KR20230028386A (ko) 인간 질환의 치료를 위한 cd38 항체
CN118754989B (zh) 一种抗her2纳米抗体及其制备方法和应用
JPWO2022104236A5 (https=)
CN111479827B (zh) 结合hERG1和hERG1/整联蛋白β1的单特异性和双特异性抗体
JPWO2021068841A5 (https=)
WO2023143273A1 (zh) 新型长效化和高活性且更安全的抗体构建体
US9464136B2 (en) Antibody-based constructs directed against tyrosine kinase receptors
JPWO2022217019A5 (https=)
TW202434635A (zh) 多特異性抗體及其醫藥用途
JP2026505164A (ja) 抗cmet抗体及びその使用方法
KR20250017214A (ko) 항cd44v6 항체 및 이들의 cd44v6 과발현 암 치료의 용도
HK40066348B (zh) 靶向bcma的抗体、双特异性抗体及其用途